Description
Indications
Indicated for the treatment of cholestatic pruritus in patients 3 months of age and older with progressive familial intrahepatic cholestasis (PFIC), and in patients 12 months of age and older with Alagille syndrome (ALGS).
Mécanisme d’action
IBAT PFIC ALGS PFIC PFIC ALGS , IBAT , , [ 12.2 ]
Pharmacologie
12.1 Mecanisme d action IBAT PFIC ALGS PFIC PFIC ALGS , IBAT , , [ 12.2 ]
Posologie
2.1 3 PFIC BYLVAY 40 mcg/kg, , 1 3 , 40 mcg/kg , 120 mcg/kg, 6 mg BYLVAY 19.5 kg BYLVAY 19.5 kg
Precautions
5.1 BYLVAY (DILI) PFIC ALGS , 6 DILI ,2 ALGS PFIC , 6 8 , , BYLVAY ,
Contre-indications
IBAT BYLVAY , [ Precautions 5.1 ]
Interactions médicamenteuses
7.1 , BYLVAY 4 4 [ Posologie (2.3)] , BYLVAY
Effets indésirables
[ Precautions(5.1)] [ Precautions(5.2)] [ Precautions(5.3)] 6.1 , , PFIC 1 24 , BYLVAY 40 mcg/kg 120 mcg/kg [ (14.1)]



